Bleeding

Among patients who underwent PCI with a drug-eluting stent and were prescribed dual antiplatelet therapy for 3 months, subsequent ticagrelor monotherapy reduced bleeding risk compared with continued DAPT regardless of DES type, according to results from the TWILIGHT-SYNERGY study.

Patients with nonvalvular atrial fibrillation and normal kidney function had increased bleeding risk with dabigatran when used alongside P-glycoprotein inhibitors diltiazem and verapamil, according to a retrospective comparative effectiveness cohort study published in JAMA Network Open.

Patients with ACS who had a bleeding event after hospital discharge had an increased risk for a subsequent cancer diagnosis within the first 6 months, according to a study published in The American Journal of Cardiology.

The incidence of serious bleeding after transcatheter aortic valve replacement was lower in patients assigned oral anticoagulation alone compared with those assigned oral anticoagulation and clopidogrel, according to data from the POPULAR-TAVI trial presented at the American College of Cardiology Scientific Session.

A meta-analysis of randomized controlled trials published in the Annals of Internal Medicine showed that dual therapy was associated with lower risk for major bleeding in patients with nonvalvular atrial fibrillation after PCI compared with triple therapy.

In a retrospective cohort study, patients with atrial fibrillation who were treated with apixaban experienced lower incidence of ischemic stroke, systemic embolism and bleeding compared with patients who received rivaroxaban.

Survey results revealed most internists perceived proton pump inhibitors were linked with numerous adverse events and recommended their discontinuation even in patients who are high risk for upper gastrointestinal bleeding.

Bleeding in the lower gastrointestinal tract increased risk for incident colorectal cancer in patients with atrial fibrillation who were treated with oral anticoagulants, according to a study published in the European Heart Journal.

Among patients with ACS who underwent PCI and received an outpatient prescription for ticagrelor or clopidogrel, ticagrelor was not associated with a significant reduction in risk for MACE, and those who received ticagrelor had more major bleeding and dyspnea, according to data from a population-based cohort study published in JAMA Internal Medicine.

PHILADELPHIA — Among patients with ACS who underwent PCI, ticagrelor monotherapy reduced bleeding risk compared with dual antiplatelet therapy, with no additional ischemic risk, according to new data from the TWILIGHT study presented at the American Heart Association Scientific Sessions.